The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
The promise of retinoids to fight against cancer
Abstract
Retinoids have a reputation for being both detrimental and beneficial: they are teratogens, but they also have tumour-suppressive capacity. Cell biology and genetics have significantly improved our understanding of the mechanisms that underlie the anti-proliferative action of retinoids. Recent elucidation of the pathways that are activated by retinoids will help us to exploit the beneficial aspects of this powerful class of compounds for cancer therapy and prevention.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Apart from the well-known indications in hypovitaminosis and skin diseases, retinoids have been successfully used in treating cancer”
From Vitamin A Update: Forms, Sources, Kinetics, Detection, Function, Deficiency, Therapeutic Use and Toxicity (2021) · cites this paper as [187]
In the citing paper
“The FDA has approved ATRA to treat cystic acne and several cancers, such as some lymphoma and leukemia”
From Vitamin A Update: Forms, Sources, Kinetics, Detection, Function, Deficiency, Therapeutic Use and Toxicity (2021) · cites this paper as [187]
Citations
Cites
The coregulator exchange in transcriptional functions of nuclear receptors
Glass, C. K., & Rosenfeld, M. G. (2000) · Genes & Development · doi:10.1101/gad.14.2.121 · Cited by 2,233 · cited 8×
“a | The t(15;17) chromosomal translocation generates the PML–RARα fusion protein that, in contrast to RARα, can efficiently dimerize or oligomerize, thereby recruiting multiple HDAC complexes and leading to ‘super-repression’ of target genes.”
BackgroundInfluentialKamei, Y., Xu, L., Heinzel, T., Torchia, J., Kurokawa, R., Gloss, B., Lin, S.-C., Heyman, R. A., Rose, D. W., Glass, C. K., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81118-6 · Cited by 2,150
Matthay, K. K., Villablanca, J. G., Seeger, R. C., Stram, D. O., Harris, R. E., Ramsay, N. K., Swift, P., Shimada, H., Black, C. T., Brodeur, G. M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910143411601 · Cited by 1,898
ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics
McPherson, K. (2000) · BMJ · doi:10.1136/bmj.321.7261.624 · Cited by 1,570
Hong, W. K., Lippman, S. M., Itri, L. M., Karp, D. D., Lee, J. S., Byers, R. M., Schantz, S. P., Kramer, A. M., Lotan, R., Peters, L. J., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199009203231205 · Cited by 1,365
The retinoids—Biology, chemistry and medicine
(1996) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(97)80793-5 · Cited by 1,178
Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells
Marks, P. A., Richon, V. M., & Rifkind, R. A. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1210 · Cited by 1,157
Embryonic retinoic acid synthesis is essential for early mouse post-implantation development
Niederreither, K., Subbarayan, V., Dollé, P., & Chambon, P. (1999) · Nature Genetics · doi:10.1038/7788 · Cited by 1,077
Role of the histone deacetylase complex in acute promyelocytic leukaemia
Lin, R. J., Nagy, L., Inoue, S., Shao, W., Miller, W. H., & Evans, R. M. (1998) · Nature · doi:10.1038/35895 · Cited by 1,062 · cited 1×
“However, high concentrations of HDAC inhibitors (HDACi) can convert even PLZF–RARα into an activator of the RA signalling pathwa”
BackgroundGrignani, F., De Matteis, S., Nervi, C., Tomassoni, L., Gelmetti, V., Cioce, M., Fanelli, M., Ruthardt, M., Ferrara, F. F., Zamir, I., et al. (1998) · Nature · doi:10.1038/35901 · Cited by 1,004 · cited 1×
“However, high concentrations of HDAC inhibitors (HDACi) can convert even PLZF–RARα into an activator of the RA signalling pathwa”
Background
Research works printed but not linked: 1
- Moon, R. C., Mehta, R. G. & Rao, K. J. V. N. in The Retinoids (eds Sporn, M. B., Roberts, A. B. & Goodman, D. S.) 573–595 (Raven, New York, 1994).
Cited by
Signal integration by JNK and p38 MAPK pathways in cancer development
Wagner, E. F., & Nebreda, Á. R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2694 · Cited by 2,586
“The JNK/JUN pathway regulates a plethora of target genes that contain AP1-binding sites, including genes that control the cell cycle, as well as survival and apoptosis, metalloproteinases and nuclear hormone receptors, such as retinoid receptor”
BackgroundAP-1: a double-edged sword in tumorigenesis
Eferl, R., & Wagner, E. F. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1209 · Cited by 2,242
“In at least some of these cases, the tumour-suppressive activity of retinoic acids is mediated by transrepression of AP-1 (Ref”
BackgroundPrinciples for modulation of the nuclear receptor superfamily
Gronemeyer, H., Gustafsson, J.-Å., & Laudet, V. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1551 · Cited by 1,226
“Whether and how this distinct characteristic of RARβ is linked to its presumptive role as a tumour supressor remains to be established (see Ref”
BackgroundSelf-citationNuclear retinoid receptors and the transcription of retinoid-target genes
Bastien, J., & Rochette-Egly, C. (2004) · Gene · doi:10.1016/j.gene.2003.12.005 · Cited by 773
“The repressive effect of retinoids on AP-1 activity has been correlated with their antitumor activity and the importance of this cross-talk for growth control is increasingly recognized (Altucci and Gronemeyer, 2001b).”
BackgroundInfluentialThe Lipophilic Bullet Hits the Targets: Medicinal Chemistry of Adamantane Derivatives
Wanka, L., Iqbal, K., & Schreiner, P. R. (2013) · Chemical Reviews · doi:10.1021/cr100264t · Cited by 696
Metadata
- Authors
- Altucci, L., & Gronemeyer, H.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Venue
- Nature Reviews Cancer
- Published
- 2001-12
- Volume
- 1
- Issue
- 3
- Pages
- 181-193
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1964224609
- Cited by
- 773
- References
- 147
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 16 · 2023: 18 · 2022: 12 · 2021: 16 · 2020: 20 · 2019: 19 · 2018: 20 · 2017: 28 · 2016: 25 · 2015: 36 · 2014: 25 · 2013: 32 · 2012: 47
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Institut National de la Santé et de la Recherche Médicale
- Centre National de la Recherche Scientifique
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- retinoids, cancer therapy, cancer prevention, tumor suppression, antiproliferative mechanism, teratogenicity, cell proliferation
- MeSH terms
- Antineoplastic Agents, Cell Differentiation, Forecasting, Humans, Models, Biological, Morphogenesis, Neoplasm Proteins, Neoplasms, Retinoids, Skin Neoplasms, Structure-Activity Relationship, Vitamin A, Leukemia, Promyelocytic, Acute, Oncogene Proteins, Fusion, Transcriptional Activation, Gene Expression Regulation, Neoplastic, Anticarcinogenic Agents, Apoptosis, Receptors, Retinoic Acid, Transcription Factor AP-1, Dimerization, Receptor Cross-Talk
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The promise of retinoids to fight against cancer. https://app.cochat.ai/papers/10.1038/35106036
- The paper
- Altucci, L., & Gronemeyer, H. (2001). The promise of retinoids to fight against cancer. Nature Reviews Cancer. https://doi.org/10.1038/35106036
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.